| Ytd | -0.45% | |
| 1y | 7.45% |
| Open | 374.89 | Prev Close | 375.04 | Low | 371.92 | High | 382.35 | Mkt Cap | 37.13B |
| Vol | 727.92K | Avg Vol | 1.03M | EPS | 7.87 | P/E | 48.05 | Forward P/E | 22.81 |
| Beta | 1.20 | Short Ratio | 4.85 | Inst. Own | 99.67% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | 11-26 | Earning | 07-29 | 50-d Avg | 347.83 | 200-d Avg | 347.62 | 1yr Est | 401.78 |
Piper Sandler analyst David Westenberg initiates coverage on Waters (NYSE:WAT) with a Neutral rat
FDA 510(k)-cleared BD BACTECâ„¢ FXI Culture System now available to U.S. market, enabling broader acce
B of A Securities analyst Derik De Bruin maintains Waters (NYSE:WAT) with a Neutral and raises th
Wolfe Research analyst Mike Polark assumes Waters (NYSE:WAT) with a Outperform rating and announc